Cargando…

Glucose and cholesterol stabilization in patients with type 2 diabetes mellitus with depressive and anxiety symptoms by problem-solving therapy in primary care centers in Mexico City

AIM: The aim of this study was to determine if the problem-solving therapy (PST) helps control metabolic variables in patients with type 2 diabetes mellitus (T2DM) who show depressive and anxiety symptoms. BACKGROUND: T2DM is a chronic-degenerative multifactorial disease. It is considered one of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Villamil-Salcedo, Valerio, Vargas-Terrez, Blanca E., Caraveo-Anduaga, Jorge, González-Olvera, Jorge, Díaz-Anzaldúa, Adriana, Cortés-Sotres, José, Pérez-Ávila, Magdalena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452974/
https://www.ncbi.nlm.nih.gov/pubmed/28870280
http://dx.doi.org/10.1017/S1463423617000512
Descripción
Sumario:AIM: The aim of this study was to determine if the problem-solving therapy (PST) helps control metabolic variables in patients with type 2 diabetes mellitus (T2DM) who show depressive and anxiety symptoms. BACKGROUND: T2DM is a chronic-degenerative multifactorial disease. It is considered one of the main public health problems in the world, and it represents an important social and economic burden. It is frequently associated with major depression and anxiety disorders, which are related with high glycated hemoglobin (HbA(1c)) concentrations and poor metabolic control. METHOD: We initially included 123 patients diagnosed with T2DM from five primary care centers (PCC) in Mexico City. HbA(1c), central glucose, and lipid profile were measured in each patient. In addition, the Kessler psychological distress scale (K-10), the Beck Depression Inventory, and the Beck Anxiety Inventory were applied at the beginning and, to those who continued, at the end of the PST, as well as four months later. FINDINGS: In total, 36 patients completed the PST and the follow-up. There was a significant decrease in depressive and anxiety symptoms (P<0.001), as well as in total cholesterol (P=0.002), HbA(1c) (P=0.05), and low-density lipoprotein (LDL) (P=0.022). The PST helps reduce depressive and anxiety symptoms and may help stabilize glucose and cholesterol up to four months. Further studies on this area are recommended. If our findings are confirmed, the PST could help improve the quality of life of thousands of individuals with psychiatric-metabolic co-morbidity who only visit PCC.